Describe the value of biosimilars in the treatment of IBD, including their cost-effectiveness and accessibility Evaluate recent healthcare policy changes and regulatory updates that impact biosimilar access and utilization Assess the latest safety/efficacy data associated with biosimilars for the treatment of IBD Identify current barriers to biosimilar access/utilization in IBD and strategies to mitigate them
- Provider:HMP Education
- Activity Link: https://www.hmpeducation.com/program/24-AIBD-205
- Start Date: 2025-01-11 06:00:00
- End Date: 2025-01-11 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
- Commercial Support: Source: Fresenius Kabi - Amount: 0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: General Surgery
Subscribe
Login
0 Comments
Oldest